Puma sinks on delayed Ph III readout

Puma Biotechnology Inc. (NASDAQ:PBYI) said Thursday in its 1Q18 earnings report that data from the Phase III NALA trial

Read the full 193 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE